Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Hormones – e.g. – prolactin – thymosin – growth factors – etc.
Reexamination Certificate
2000-05-03
2002-12-17
Saoud, Christine J. (Department: 1646)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Hormones, e.g., prolactin, thymosin, growth factors, etc.
C435S069400, C435S070100, C530S350000, C536S023400
Reexamination Certificate
active
06495668
ABSTRACT:
BACKGROUND OF THE INVENTION
In multicellular animals, cell growth, differentiation, and migration are controlled by polypeptide growth factors. These growth factors play a role in both normal development and pathogenesis, including the development of solid tumors.
Polypeptide growth factors influence cellular events by binding to cell-surface receptors, many of which are tyrosine kinases. Binding initiates a chain of signalling events within the cell, which ultimately results in phenotypic changes, such as cell division, protease production, and cell migration.
Growth factors can be classified into families on the basis of structural similarities. One such family, the PDGF (platelet derived growth factor) family, is characterized by a dimeric structure stabilized by disulfide bonds. This family includes PDGF, the placental growth factors (PlGFs), and the vascular endothelial growth factors (VEGFs). The individual polypeptide chains of these proteins form characteristic higher-order structures having a bow tie-like configuration about a cystine knot, formed by disulfide bonding between pairs of cysteine residues. Hydrophobic interactions between loops contribute to the dimerization of the two monomers. See, Daopin et al.,
Science
257:369, 1992; Lapthorn et al.,
Nature
369:455, 1994. Members of this family are active as both homodimers and heterodimers. See, for example, Heldin et al.,
EMBO J
. 7:1387-1393, 1988; Cao et al.,
J. Biol. Chem
. 271:3154-3162, 1996. The cystine knot motif and “bow tie” fold are also characteristic of the growth factors transforming growth factor-beta (TGF-&bgr;) and nerve growth factor (NGF), and the glycoprotein hormones. Although their amino acid sequences are quite divergent, these proteins all contain the six conserved cysteine residues of the cystine knot.
Five vascular endothelial growth factors have been identified: VEGF, also known as vascular permeability factor (Dvorak et al.,
Am. J. Pathol
. 146:1029-1039, 1995); VEGF-B (Olofsson et al.,
Proc. Natl. Acad. Sci. USA
93:2567-2581, 1996; Hayward et al., WIPO Publication WO 96/27007); VEGF-C (Joukov et al.,
EMBO J
. 15:290-298, 1996); VEGF-D (Oliviero, WO 97/12972; Achen et al., WO 98/07832), and zvegf3 (SEQ ID NO:32 and NO:33; co-pending U.S. patent applications Ser. Nos. 60/111,173, 60/142,576, and 60/161,653). Five VEGF polypeptides (121, 145, 165, 189, and 206 amino acids) arise from alternative splicing of the VEGF mRNA.
VEGFs stimulate the development of vasculature through a process known as angiogenesis, wherein vascular endothelial cells re-enter the cell cycle, degrade underlying basement membrane, and migrate to form new capillary sprouts. These cells then differentiate, and mature vessels are formed. This process of growth and differentiation is regulated by a balance of pro-angiogenic and anti-angiogenic factors. Angiogenesis is central to normal formation and repair of tissue, occuring in embryo development and wound healing. Angiogenesis is also a factor in the development of certain diseases, including solid tumors, rheumatoid arthritis, diabetic retinopathy, macular degeneration, and atherosclerosis.
A number of proteins from vertebrates and invertebrates have been identified as influencing neural development. Among those molecules are members of the neuropilin family and the semaphorin/collapsin family.
Three receptors for VEGF have been identified: KDR/Flk-1 (Matthews et al.,
Proc. Natl. Acad. Sci. USA
88:9026-9030, 1991), Flt-1 (de Vries et al.,
Science
255:989-991, 1992), and neuropilin-1 (Soker et al.,
Cell
92:735-745, 1998). Neuropilin-1 is also a receptor for PIGF-2 (Migdal et al.,
J. Biol. Chem
. 273: 22272-22278, 1998).
Neuropilin-1 is a cell-surface glycoprotein that was initially identified in Xenopus tadpole nervous tissues, then in chicken, mouse, and human. The primary structure of neuropilin-1 is highly conserved among these vertebrate species. Neuropilin-1 has been demonstrated to be a receptor for various members of the semaphorin family including semaphorin III (Kolodkin et al.,
Cell
90:753-762, 1997), Sema E and Sema IV (Chen et al.,
Neuron
19:547-559, 1997). A variety of activities have been associated with the binding of neuropilin-1 to its ligands. For example, binding of semaphorin III to neuropilin-1 can induce neuronal growth cone collapse and repulsion of neurites in vitro (Kitsukawa et al.,
Neuron
19: 995-1005, 1997). Experiments with transgenic mice indicate the involvement of neuropilin-1 in the development of the cardiovascular system, nervous system, and limbs. See, for example, Kitsukawa et al.,
Development
121:4309-4318, 1995; and Takashima et al., American Heart Association 1998 Meeting, Abstract #3178.
Semaphorins are a large family of molecules which share the defining semaphorin domain of approximately 500 amino acids. Dimerization is believed to be important for functional activity (Klostermann et al.,
J. Biol. Chem
. 273:7326-7331, 1998). Collapsin-1, the first identified vertebrate member of the semaphorin family of axon guidance proteins, has also been shown to form covalent dimers, with dimerization necessary for collapse activity (Koppel et al.,
J. Biol. Chem
. 273:15708-15713, 1998). Semaphorin III has been associated in vitro with regulating growth clone collapse and chemorepulsion of neurites. Semaphorins have been shown to be responsible for a variety of developmental effects, including effects on sensory afferent innervation, skeletal and cardiac development (Fehar et al.,
Nature
383:525-528, 1996), immunosuppression via inhibition of cytokines (Mangasser-Stephan et al.,
Biochem. Biophys. Res. Comm
. 234:153-156, 1997), and promotion of B-cell aggregation and differentiation (Hall et al.,
Proc. Natl. Acad. Sci. USA
93:11780-11785, 1996). CD100 has also been shown to be expressed in many T-cell lymphomas and may be a marker of malignant T-cell neoplasms (Dorfman et al.,
Am. J. Pathol
. 153:255-262, 1998). Transcription of the mouse semaphorin gene, M-semaH, correlates with metastatic ability of mouse tumor cell lines (Christensen et al.,
Cancer Res
. 58:1238-1244, 1998).
The role of growth factors, other regulatory molecules, and their receptors in controlling cellular processes makes them likely candidates and targets for therapeutic intervention. Platelet-derived growth factor, for example, has been disclosed for the treatment of periodontal disease (U.S. Pat. No. 5,124,316), gastrointestinal ulcers (U.S. Pat. No. 5,234,908), and dermal ulcers (Robson et al.,
Lancet
339:23-25, 1992). Inhibition of PDGF receptor activity has been shown to reduce intimal hyperplasia in injured baboon arteries (Giese et al., Restenosis Summit VIII, Poster Session #23, 1996; U.S. Pat. No. 5,620,687). PDGF has also been shown to stimulate bone cell replication (reviewed by Canalis et al.,
Endocrinology and Metabolism Clinics of North America
18:903-918, 1989), to stimulate the production of collagen by bone cells (Centrella et al.,
Endocrinology
125:13-19, 1989) and to be useful in regenerating periodontal tissue (U.S. Pat. No. 5,124,316; Lynch et al.,
J. Clin. Periodontol
. 16:545-548, 1989). Vascular endothelial growth factors (VEGFs) have been shown to promote the growth of blood vessels in ischemic limbs (Isner et al.,
The Lancet
348:370-374, 1996), and have been proposed for use as wound-healing agents, for treatment of periodontal disease, for promoting endothelialization in vascular graft surgery, and for promoting collateral circulation following myocardial infarction (WIPO Publication No. WO 95/24473; U.S. Pat. No. 5,219,739). VEGFs are also useful for promoting the growth of vascular endothelial cells in culture. A soluble VEGF receptor (soluble flt-1) has been found to block binding of VEGF to cell-surface receptors and to inhibit the growth of vascular tissue in vitro (
Biotechnology News
16(17):5-6, 1996).
In view of the proven clinical utility of polypeptide growth factors, there is a need in the art for additional such molecules for use as therapeutic agents, diagnostic agents, and re
Gilbert Teresa
Gilbertson Debra G.
Hart Charles E.
Sheppard Paul O.
Chernyshev Olga N.
Parker Gary E.
Saoud Christine J.
ZymoGenetics Inc.
LandOfFree
Growth factor homolog ZVEGF4 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Growth factor homolog ZVEGF4, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Growth factor homolog ZVEGF4 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2951506